|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: Impact of bilharziasis and fibrosis stage显示文摘AIM: To evaluate pegylated interferon alpha2a (PegIFN- α2a) in Egyptian patients with HCV genotype 4, and the impact of pretreatment viral load, co-existent bilharziasis and histological liver changes on response rate. METHODS: A total of 73 na?ve patients (61 with history of bilharziasis) with compensated chronic HCV genotype 4 were enrolled into: group A (38 patients) who received 180 mg PegIFN-alpha2a subcutaneously once weekly for a year and group B (35 patients) received IFN alpha-2a 3 MU 3 times weekly. Ribavirin was added to each regimen at a dose of 1200 mg. Patients were followed for 72 wk and sustained response was assessed. RESULTS: Significant improvement in both end of treatment response (ETR) (P < 0.002) and sustained response (SR) (P < 0.05) was noted with pegylated interferon, where ETR was achieved in 29 (76.3%) and 14 patients (40%) in both groups respectively, and 25 patients in group A (65.8%) and 9 (25.7%) in group B could retain negative viraemia by the end of follow up period. Sustained virological response (SVR) showed a significant negative correlation with age and positive correlation with pretreatment inflammation in patients receiving PegIFN. Viral clearance after 3 mo of therapy was associated with high incidence of ETR and SR (P < 0.001), but without significant difference between both forms of interferon. Significant improvement in response was achieved in patients with high grade fibrosis (grade 3 and 4) with PegIFN-α2a, where SR was seen in 5 out of 13 patients in group A, but none in group B. There was no significant difference in response betweenbilharzial and non-bilharzial patients in both groups. In terms of safety and tolerability, neutropenia was the predominant side effect; both drugs were comparable. CONCLUSION: PegIFN-α2a combined with ribavirin results in improvement in sustained response in HCV genotype 4, irrespective of history of bilharzial infestation. | MF Derbala SR Al Kaabi NZ El Dweik F Pasic MT Butt R Yakoob A Al-Marri AM Amer N Morad A Bener | 2006 | World Journal of Gastroenterology2006，12，35： | 3 |
| 2 | Increased Quality of Life Among Hepatocellular Carcinoma Patients Treated with Radioembolization, Compared with Chemoembolization显示文摘 | Riad Salem Margaret Gilbertsen Zeeshan Butt Khairuddin Memon Michael Vouche Ryan Hickey Talia Baker Michael M. Abecassis Rohi Atassi Ahsun Riaz David Cella James L. Burns Daniel Ganger Al B. Benson Mary F. Mulcahy Laura Kulik Robert Lewandowski | 2013 | Clinical Gastroenterology and Hepatology2013，，： | 2 |
| 3 | Nutrient Adequacy and Diet Quality in Non-Overweight and Overweight Hispanic Children of Low Socioeconomic Status:The Viva la Familia Study显示文摘 | WILSON TA ADOLPH AL BUTTE NF | 2009 | Journal of the American Dietetic Association2009，109，6： | 1 |
| 4 | Prevalence and risks factors of age- related macular degeneration in Oklahoma Indians:the Vision Keepers Study显示文摘 | Butt AL Lee ET Klein R | 2011 | Ophthalmology2011，118，： | 1 |
| 5 | Important and relevant symptoms including pain concerns in hepatocellular carcinoma (HCC): a patient interview study显示文摘 | Karen Kaiser Rajiv Mallick Zeeshan Butt Mary F. Mulcahy Al B. Benson David Cella | 2014 | Supportive Care in Cancer2014，，4： | 1 |
| 6 | Effectiveness of a home program of ischemic pressure followed by sustained stretch for treatment of myofascial trigger points显示文摘 | Hanten WP Olson SL Butts NL Nowicki AL | 2000 | Phys Ther2000，80，10： | 1 |
| 7 | Physical activityin non overweight and overweight Hispanic children andadolescents显示文摘 | Butte NF Puyau MR Adolph AL | 2007 | Med Sci Sports Exerc2007，39，： | 1 |
| 8 | Diabetes mellitus and decompensated cirrhosis: risk of hepatic encephalopathy in different age groups显示文摘 | Zeeshan Butt Nauman A Jadoon Osman N Salaria et al | 2013 | Journal of diabetes2013，5，4： | 1 |
| 9 | Digestive system involvement and clinical outcomes among COVID-19 patients:A retrospective cohort study from Qatar显示文摘BACKGROUND Coronavirus disease 2019(COVID-19)caused by the severe acute respiratory syndrome coronavirus 2 virus most commonly presents with respiratory symptoms.While gastrointestinal(GI)manifestations either at presentation or during hospitalization are also common,their impact on clinical outcomes is controversial.Some studies have described worse outcomes in COVID-19 patients with GI symptoms,while others have shown either no association or a protective effect.There is a need for consistent standards to describe GI symptoms in COVID-19 patients and to assess their effect on clinical outcomes,including mortality and disease severity.AIM To investigate the prevalence of GI symptoms in hospitalized COVID-19 patients and their correlation with disease severity and clinical outcomes.METHODS We retrospectively reviewed 601 consecutive adult COVID-19 patients requiring hospitalization between May 1-15,2020.GI symptoms were recorded at admission and during hospitalization.Demographic,clinical,laboratory,and treatment data were retrieved.Clinical outcomes included all-cause mortality,disease severity at presentation,need for intensive care unit(ICU)admission,development of acute respiratory distress syndrome,and need for mechanical ventilation.Multivariate logistic regression model was used to identify independent predictors of the adverse outcomes.RESULTS The prevalence of any GI symptom at admission was 27.1%and during hospitalization was 19.8%.The most common symptoms were nausea(98 patients),diarrhea(76 patients),vomiting(73 patients),and epigastric pain or discomfort(69 patients).There was no difference in the mortality between the two groups(6.21%vs 5.5%,P=0.7).Patients with GI symptoms were more likely to have severe disease at presentation(33.13%vs 22.5%,P<0.001)and prolonged hospital stay(15 d vs 14 d,P=0.04).There was no difference in other clinical outcomes,including ICU admission,development of acute respiratory distress syndrome,or need for mechanical ventilation.Drugs associated with the development of GI symptoms during hospitalization were ribavirin(diarrhea 26.37%P<0.001,anorexia 17.58%,P=0.02),hydroxychloroquine(vomiting 28.52%,P=0.009)and lopinavir/ritonavir(nausea 32.65%P=0.049,vomiting 31.47%P=0.004,and epigastric pain 12.65%P=0.048).In the multivariate regression analysis,age>65 years was associated with increased mortality risk[odds ratio(OR)7.53,confidence interval(CI):3.09-18.29,P<0.001],ICU admission(OR:1.79,CI:1.13-2.83,P=0.012),and need for mechanical ventilation(OR:1.89,CI:1.94-2.99,P=0.007).Hypertension was an independent risk factor for ICU admission(OR:1.82,CI:1.17-2.84,P=0.008)and need for mechanical ventilation(OR:1.66,CI:1.05-2.62,P=0.028).CONCLUSION Patients with GI symptoms are more likely to have severe disease at presentation;however,mortality and disease progression is not different between the two groups. | Muhammad Umair Khan Kamran Mushtaq Deema Hussam Alsoub Phool Iqbal Fateen Ata Hammad Shabir Chaudhry Fatima Iqbal Girisha Balaraju Muna A Al Maslamani Betsy Varughese Rajvir Singh Khalid Al Ejji Saad Al Kaabi Yasser Medhat Kamel Adeel Ajwad Butt | 2021 | World Journal of Gastroenterology2021，27，46： | 1 |
| 10 | Dialysis access fistulas: lrealment of stenosis by transluminal angioplasty 显示文摘 | Glanz S Grdon DH Butt KMH el al | 1984 | Radiology1984，152，3： | 1 |
| 11 | Physical activity in non overweight and overweight Hispanic children and adolescents 显示文摘 | Butte NF Puyau MR Adolph AL | 2007 | Med Sci Sports Exerc2007，39，： | 1 |
| 12 | Randomized phase II study of gemcitabine plus cisplatin or carboplatin, with or without cetuximab, as first- line therapy for patients with advanced or metastatic non small- cell lung cancer 显示文摘 | Butts CA Bodkin D Middleman EL et al | 2007 | J Clin Oncol2007，25，36： | 1 |
| 13 | Energy requirements duringpregnancy based on total energy expenditure and energy deposition显示文摘 | Butte NF Wong WW Treuth MS ef al | 2004 | Am J Clin Nutr2004，，79： | 1 |
| 14 | SUMO fusion technologyfor difficult -to-express proteins显示文摘 | Butt T R Edavettal S C HalI J P ei al | 2005 | Protein Expr Purif2005，43，1： | 1 |
| 15 | Production of endometrial matrixmetalloproteinases but not their tissue inhibitors, is modulated by progesterone withdrawal in an in vitro model for menstruation显示文摘 | Salamonsen LA Butt AR Hammond FR el al | 1997 | J Clin Endocrinol Metab1997，82，： | 1 |
| 16 | Prevalence and risks factors of age-related macular degenera- tion in Oklahoma Indians: the Vision Keepers Study 显示文摘 | Butt AL Lee ET Klein R Russell D Ogola G Warn A | 2011 | Oph- thalmology2011，118，7： | 1 |
| 17 | clinical and serological association with anti-RNA polymerase antibodies in systemic sclerosis显示文摘 | Harvey GR Butts S Rands AL | 1999 | Clin Exp Immunol1999，117，： | 1 |
| 18 | Deformation and Height Anomaly of Soft Surfaces Studied with an AFM显示文摘 | Weisenhorn AL Khorsandi M Kasas S Gotzos V Butt H- J | 1993 | Nanoteehnology1993，4，： | 1 |
| 19 | Tissue inhibitors of metalloproteinases in endometrium of ovariectomized steroid-treated ewes and during the estrous cycle and early pregnancy显示文摘 | Hampton AL Butt AR Riley SC | 1995 | Biol Reprod1995，53，2： | 1 |
| 20 | Tissue inhibitors of metalloproteinases in endometrium of ovariectomized steroidtreated ewes and during the estrous cycle and early pregnancy 显示文摘 | Hampton AL Butt AR Riley SC | 1995 | Biol Reprod1995，53，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员